个人简介

浙江大学求是讲席教授，浙大第一医院泌尿医学科学与技术研究所所长。原美国梅奥医学中心Gordon H and Violet Bartels讲席教授、梅奥基础泌尿研究中心主任、梅奥癌症中心癌症基因组-信号传导-细胞转移研究方向共同负责人，曾任美国基础泌尿研究学会（SBUR）主席。是前列腺癌研究领域国际顶级专家，在肿瘤转录组学、表观遗传学、治疗抗性和新药研发等方向取得了一系列突破性重大成果，以通讯或第一作者在Science、 Nature Medicine、Cancer Cell、 Nature Cell Biology、 Molecular Cell、 Science Advances等杂志上发表高质量论文170多篇，h-指数62。作为课题首席科学家（PI），承担美国国立卫生研究院（NIH）R01基金9项，美国国防部（DOD）前列腺癌研究项目3项和美国前列腺癌症基金会（PCF）课题1项，累计获得科研资助2200余万美元。作为第一发明人，申请US/PCT专利31项、授权4项，并有两项研究已进入多中心二期临床试验。

代表性成果

1.Sun R, Yan B, Li H, Ding D, Wang L, Pang J, Ye D, Huang H. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis. Cancer Res. 2023 Oct 2; 83 (19):3192-3204

2.Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, Lujambio A, Karnes J, Knudsen KE, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discov. 2023 Sep 7 Epub 2023 Sept 07
3.Ding D, Blee AM, Zhang J, Pan Y, Becker NA, Maher LJ 3rd, Jimenez R, Wang L, Huang H. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Nat Commun. 2023 Aug 3; 14 (1):4671 Epub 2023 Aug 03

4.Zhang J, Wei J, Sun R, Sheng H, Yin K, Pan Y, Jimenez R, Chen S, Cui XL, Zou Z, Yue Z, Emch MJ, Hawse JR, Wang L, He HH, Xia S, Han B, He C, Huang H. A lncRNA from the FTO locus acts as a suppressor of the m(6)A writer complex and p53 tumor suppression signaling. Mol Cell. 2023 Aug 3; 83 (15):2692-2708.e7 Epub 2023 July 20
5.Ma J, Zhou Y, Pan P, Yu H, Wang Z, Li LL, Wang B, Yan Y, Pan Y, Ye Q, Liu T, Feng X, Xu S, Wang K, Wang X, Jian Y, Ma B, Fan Y, Gao Y, Huang H, Li L. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks. Nat Commun. 2023 Mar 31; 14(1):1810. 

6. Zhang J, Wei J, Sun R, Sheng H, Yin K, Pan Y, Jimenez R, Chen S, Cui XL, Zou Z, Yue Z, Emch MJ, Hawse JR, Wang L, He HH, Xia S, Han B, He C, Huang H. A lncRNA from the FTO locus acts as a suppressor of the m(6)A writer complex and p53 tumor suppression signaling. Mol Cell. 2023 Aug 3; 83 (15):2692-2708.e7 Epub 2023 July 20

7. Ding D, Blee AM, Zhang J, Pan Y, Becker NA, Maher LJ 3rd, Jimenez R, Wang L, Huang H. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Nat Commun. 2023 Aug 3; 14 (1):4671 Epub 2023 Aug 03

8. Ma J, Zhou Y, Pan P, Yu H, Wang Z, Li LL, Wang B, Yan Y, Pan Y, Ye Q, Liu T, Feng X, Xu S, Wang K, Wang X, Jian Y, Ma B, Fan Y, Gao Y, Huang H, Li L. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks. Nat Commun. 2023 Mar 31; 14(1):1810.

9. Orme JJ, Mer G, Huang H. Hidden tricks in MATH: Hypermorphic mutations in SPOP tumor suppressor explained by cryo-EM. Mol Cell 2023 Mar 2; 83 (5):655-656

10. Ding D, Zheng R, Tian Y, Jimenez R, Hou X, Weroha SJ, Wang L, Shi L, Huang H. Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. Nat Commun. 2022 Oct 23; 13 (1):6311

11. Sun R, Wei T, Ding D, Zhang J, Chen S, He HH, Wang L, Huang H. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2022 Sep 27; 119 (39):e2205509119 Epub 2022 Sept 21

12. Ma J, Shi Q, Cui G, Sheng H, Botuyan MV, Zhou Y, Yan Y, He Y, Wang L, Wang Y, Mer G, Ye D, Wang C, Huang H. SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. Nat Commun. 2021 Oct 1; 12 (1):5779 Epub 2021 Oct 01

13. Shao J, Yan Y, Ding D, Wang D, He Y, Pan Y, Yan W, Kharbanda A, Li HY, Huang H. Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. Adv Sci (Weinh). 2021 Oct; 8 (20):e2102555 Epub 2021 Aug 16

14. Zhang J, Gao K, Xie H, Wang D, Zhang P, Wei T, Yan Y, Pan Y, Ye W, Chen H, Shi Q, Li Y, Zhao SM, Hou X, Weroha SJ, Wang Y, Zhang J, Karnes RJ, He HH, Wang L, Wang C, Huang H. SPOP mutation induces DNA methylation via stabilizing GLP/G9a. Nat Commun. 2021 Sep 29; 12 (1):5716 Epub 2021 Sept 29

15. He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H, Hollern DP, Zhang X, Ma J, Wen S, Xie H, Yan Y, Pan Y, Hou X, Tang X, Suman VJ, Carter JM, Weinshilboum R, Wang L, Kalari KR, Weroha SJ, Bryce AH, Boughey JC, Dong H, Perou CM, Ye D, Goetz MP, Ren S, Huang H. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest. 2021 Jul 15; 131(14).

16. Wang D, Ma J, Botuyan MV, Cui G, Yan Y, Ding D, Zhou Y, Krueger EW, Pei J, Wu X, Wang L, Pei H, McNiven MA, Ye D, Mer G, Huang H. ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. Sci Adv. 2021 Jun; 7 (25) Epub 2021 June 18

17. He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, Wang L, Gleave ME, Wang Y, Shi L, Huang H. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 2021 Mar 9; 12 (1):1521 Epub 2021 Mar 09

18. Tang B, Sun R, Wang D, Sheng H, Wei T, Wang L, Zhang J, Ho TH, Yang L, Wei Q, Huang H. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. Proc Natl Acad Sci U S A. 2021 Feb 23; 118 (8)

19. Hong Z, Zhang W, Ding D, Huang Z, Yan Y, Cao W, Pan Y, Hou X, Weroha SJ, Karnes RJ, Wang D, Wu Q, Wu D, Huang H. DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3ß and WEE1. Mol Cell. 2020 Sep 17; 79(6):1008-1023.e4. Epub 2020 Aug 31.

20. Orme JJ, Huang H. Microenvironment-Mediated Resistance to Anti-Androgen Therapy. Cancer Cell 2020 Aug 10; 38 (2):155-157

21. Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-kappaB Activation and PD-L1 Expression. Mol Cell. 2019 Jan 3; 73 (1):22-35.e6 Epub 2018 Dec 06

22. Jin X, Yan Y, Wang D, Ding D, Ma T, Ye Z, Jimenez R, Wang L, Wu H, Huang H. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. Mol Cell. 2018 Aug 16; 71 (4):592-605.e4 Epub 2018 July 26

23. Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017 Sep; 23 (9):1055-1062 Epub 2017 Aug 14

24. An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X, Cui Y, Wang L, Pan Y, Zhang X, Zhu Y, Wang C, Halling GC, Cheng L, Sukov WR, Karnes RJ, Vasmatzis G, Zhang Q, Zhang J, Cheville JC, Yan J, Sun Y, Huang H. Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Mol Cell. 2015 Sep 17; 59 (6):904-16 Epub 2015 Sept 03

25. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014 Feb 27; 6 (4):657-69 Epub 2014 Feb 06

26. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol. 2010 Nov; 12(11):1108-14. Epub 2010 Oct 10.

27. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. 2006 Oct 13; 314 (5797):294-7